Krystal Biotech Inc (KRYS)
177.64
-4.63
(-2.54%)
USD |
NASDAQ |
Jul 02, 16:00
177.64
0.00 (0.00%)
After-Hours: 20:00
Krystal Biotech Research and Development Expense (Annual): 46.43M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 46.43M |
| December 31, 2022 | 42.46M |
| December 31, 2021 | 27.88M |
| December 31, 2020 | 17.94M |
| Date | Value |
|---|---|
| December 31, 2019 | 15.62M |
| December 31, 2018 | 7.761M |
| December 31, 2017 | 3.208M |
| December 31, 2016 | 0.741M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
15.62M
Minimum
2019
46.43M
Maximum
2023
30.07M
Average
27.88M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Biomarin Pharmaceutical Inc | 746.77M |
| Integra Lifesciences Holdings Corp | 104.19M |
| OraSure Technologies Inc | 33.73M |
| Madrigal Pharmaceuticals Inc | 272.35M |
| Agios Pharmaceuticals Inc | 295.53M |